Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 5/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679648 | 0.84 | AURKA (0.69) | AURKAAURKBKCNQ3KCNQ2 | |
| SCHEMBL686667 | 0.77 | AURKA (0.57) | AURKAAURKBKDR | |
| SCHEMBL678061 | 0.75 | AURKB (0.64) | AURKAAURKBEGFRINCENPRPS6KB1 | |
| SCHEMBL13553354 | 0.75 | EGFR (0.51) | EGFRERBB2KDRMEN1NPC1 | |
| SCHEMBL678591 | 0.74 | LMNA (0.68) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL678217 | 0.72 | AURKB (0.59) | AURKAAURKBEGFRINCENPRPS6KB1 | |
| SCHEMBL678945 | 0.72 | AURKA (0.68) | AURKAAURKBKCNQ3KCNQ2 | |
| SCHEMBL3454662 | 0.70 | AURKA (1.00) | AURKAAURKB | |
| SCHEMBL6814178 | 0.70 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL26784735 | 0.69 | AURKB (0.60) | AURKAAURKBEGFRINCENPERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885EGFR 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.